Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 3/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1608225 | 0.79 | G6PD (0.39) | G6PDCASP3KDM4EALDH1A1HPGD | |
| SCHEMBL28348926 | 0.77 | G6PD (0.56) | G6PDCASP3MIFKDM4EALDH1A1 | |
| SCHEMBL17191871 | 0.76 | CA12 (0.38) | SRCGPR35 | |
| SCHEMBL19425902 | 0.76 | NPC1 (0.35) | SRCGPR35HPGD | |
| SCHEMBL15680241 | 0.69 | G6PD (0.36) | G6PDCASP3KDM4EALDH1A1HPGD | |
| SCHEMBL15680200 | 0.69 | SRC (0.48) | SRCKDM4EALDH1A1CYP3A4THRB | |
| SCHEMBL15680602 | 0.69 | ESR1 (0.36) | CASP3 | |
| SCHEMBL50008 | 0.67 | CASP3 (1.00) | G6PDCASP3KDM4EALDH1A1HPGD | |
| SCHEMBL92179 | 0.66 | G6PD (0.51) | G6PDCASP3MIFKDM4EALDH1A1 | |
| SCHEMBL17300638 | 0.65 | HPGD (0.33) | G6PDKDM4EALDH1A1CYP3A4THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20150344502-A1 | CEPHEM COMPOUND | SHIONOGI & CO., LTD. (JP) | 2015-12-03 | — | — | US | disclosed |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-10-22 | — | — | US | disclosed |
| WO-2014068388-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-05-08 | — | — | WO | disclosed |
| US-8318785-B2 | Pharmaceutical compounds | ORION CORPORATION (FI) | 2012-11-27 | — | — | US | disclosed |
| US-20110086852-A2 | PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2011-04-14 | — | — | US | disclosed |
| EP-1910325-B1 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORP (FI) | 2010-10-06 | — | — | EP | disclosed |
| US-20090209532-A1 | PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | CEP170, CES2, CMBL | G6PD 286/4885CASP3 2641/4885SRC 4027/4885 |
| US-20090209532-A1 | PHARMACEUTICAL COMPOUNDS | COMT, CYP2C19, UGT1A1 | G6PD 96/4885CASP3 4186/4885SRC 2835/4885 |
| US-20150344502-A1 | CEPHEM COMPOUND | PRMT6, CEP170, NR0B1 | G6PD 1736/4885CASP3 4093/4885SRC 1614/4885 |
| US-20110086852-A2 | PHARMACEUTICAL COMPOUNDS | COMT, CYP2C19, CYP3A4 | G6PD 207/4885CASP3 3795/4885SRC 1244/4885 |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | CEP170, ABL1, CEPT1 | G6PD 647/4885CASP3 1606/4885SRC 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.